Avirup Guha

Dr. Avirup Guha

Medical College of Georgia at Augusta University, Augusta, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
GCGlobal Burden of Disease 2019 Cancer Collaboration
Global Burden of Disease 2019 Cancer Collaboration
JKJonathan M. Kocarnik
Jonathan M. Kocarnik
KCKelly Compton
Kelly Compton
FDFrances E. Dean
Frances E. Dean
WFWeijia Fu
Weijia Fu
LFLisa M. Force
Lisa M. Force
Cancers are a major contributor to disease burden worldwide, and projections forecast that global cancer burden will continue to grow for at least the next 2 decades.1-4 The United Nations (UN) Sustainable Development Goals (SDGs) recognize the need for reducing cancer burden as part of target 3.4, stating “By 2030, reduce by one third premature mortality from noncommunicable diseases [NCDs] through prevention and treatment and promote mental health and well-being.”5 Most countries will need to accelerate their efforts to reduce NCD burden, including cancer, to meet this SDG target.6,7 Increasing the pace of progress will be particularly critical given the ongoing COVID-19 pandemic, which has led to delays and disruptions in cancer screenings, diagnosis, and treatment around the world.8-12

1 June 2020 in JACC: Cardiooncology
Verified
Journal Article
Open access
STSara Tyebally
Sara Tyebally
DCDaniel Chen
Daniel Chen
SBSanjeev Bhattacharyya
Sanjeev Bhattacharyya
AMAbdallah Mughrabi
Abdallah Mughrabi
ZHZeeshan Hussain
Zeeshan Hussain
Avirup GuhaAvirup Guha
Avirup Guha
Cardiac masses are rare, but remain an important component of cardio-oncology practice. These include benign tumors, malignant tumors (primary and secondary) and tumor-like conditions (e.g., thrombus, Lambl’s excrescences, and pericardial cyst). The advent of multimodality imaging has enabled identification of the etiology of cardiac masses in many cases, especially in conjunction with information from clinical settings. This paper provides a comprehensive review of the epidemiology, clinical presentation, imaging, diagnosis, management, and outcomes of cardiac masses.

28 November 2019 in Blood
Verified
Journal Article
Open access
PDF file
TDTyler Dickerson
Tyler Dickerson
TWTracy Wiczer
Tracy Wiczer
AWAllyson Waller
Allyson Waller
JPJennifer Philippon
Jennifer Philippon
KPKyle Porter
Kyle Porter
DADaniel Addison
Daniel Addison
In a retrospective analysis, Dickerson et al report that the incidence of hypertension in patients treated with ibruitinib is nearly 80% and is associated with an increased rate of adverse cardiovascular events, primarily atrial fibrillation. Cardiac events can be reduced by treating the hypertension.

1 October 2019 in JACC
Verified
Journal Article
Open access
RKRaymond Y. Kwong
Raymond Y. Kwong
YGYin Ge
Yin Ge
KSKevin Steel
Kevin Steel
SBScott Bingham
Scott Bingham
SAShuaib Abdullah
Shuaib Abdullah
OSOrlando P. Simonetti
Orlando P. Simonetti
Stress cardiac magnetic resonance imaging (CMR) has demonstrated excellent diagnostic and prognostic value in single-center studies. This study sought to investigate the prognostic value of stress CMR and downstream costs from subsequent cardiac testing in a retrospective multicenter study in the United States. In this retrospective study, consecutive patients from 13 centers across 11 states who presented with a chest pain syndrome and were referred for stress CMR were followed for a target period of 4 years. The authors associated CMR findings with a primary outcome of cardiovascular death or nonfatal myocardial infarction using competing risk-adjusted regression models and downstream costs of ischemia testing using published Medicare national payment rates. In this study, 2,349 patients (63 ± 11 years of age, 47% female) were followed for a median of 5.4 years. Patients with no ischemia or late gadolinium enhancement (LGE) by CMR, observed in 1,583 patients (67%), experienced low annualized rates of primary outcome (4-fold higher annual primary outcome rate and a >10-fold higher rate of coronary revascularization during the first year after CMR. Patients with ischemia and LGE both negative had low average annual cost spent on ischemia testing across all years of follow-up, and this pattern was similar across the 4 practice environments of the participating centers. In a multicenter U.S. cohort with stable chest pain syndromes, stress CMR performed at experienced centers offers effective cardiac prognostication. Patients without CMR ischemia or LGE experienced a low incidence of cardiac events, little need for coronary revascularization, and low spending on subsequent ischemia testing. (Stress CMR Perfusion Imaging in the United States [SPINS]: A Society for Cardiovascular Resonance Registry Study; NCT03192891).

14 November 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Avirup GuhaAvirup Guha
Avirup Guha
MFMichael Fradley
Michael Fradley
SDSusan Dent
Susan Dent
NWNeal Weintraub
Neal Weintraub
MLMaryam B Lustberg
Maryam B Lustberg
DADaniel Addison
Daniel Addison
Aims: The national incidence, risk factors, and associated mortality of atrial fibrillation (AF) in breast cancer patients are unknown. Methods and results: Using the Surveillance, Epidemiology, and End Results-Medicare-linked database, we identified females, ≥66 years old, with a new primary diagnosis of breast cancer from 2007 through 2014. These patients were individually matched 1:1 to Medicare enrolees without cancer, and each pair was followed for 1 year to identify a primary outcome of AF. Cumulative incidence was calculated using competing risk survival statistics. Following this, identifying risk factors of AF among breast cancer patients was conducted using the adjusted Cox proportional hazards model. Finally, Kaplan–Meier methods and adjusted Cox proportional hazards modelling were performed to estimate mortality in breast cancer patients with incident and prevalent AF. This study included 85 423 breast cancer patients. Among these 9425 (11.0%) had AF diagnosis prior to the breast cancer diagnosis. New-onset AF was diagnosed in 2993 (3.9%) patients in a 1-year period after the breast cancer diagnosis [incidence 3.3%, 95% confidence interval (CI) 3.0–3.5%, at 1 year; higher rate in the first 60 days (0.6%/month)]. Comparatively, the incidence of new-onset AF in matched non-cancer controls was 1.8% (95% CI 1.6–2.0%). Apart from traditional demographic and cardiovascular risk factors, breast cancer stage was strongly associated with the development of AF [American Joint Committee on Cancer (AJCC) Stage II/III/IV vs. I: adjusted hazard ratio (aHR) 1.51/2.63/4.21, respectively]. New-onset AF after breast cancer diagnosis (aHR 3.00) is associated with increased 1-year cardiovascular mortality. Conclusion: AF incidence is significantly higher in women after a breast cancer diagnosis. Higher breast cancer stages at diagnos are significantly associated with a higher risk of AF. New-onset AF in the new breast cancer diagnosis setting increases 1-year cardiovascular mortality but not breast cancer-related mortality. Key Question: What are the incidence, prevalence, risk factors and mortality outcomes of atrial fibrillation (AF) in a multi-ethnic representative United States cohort of breast cancer patients? Key Finding: Annual incidence for AF is 3.9% with highest rate in the first 60 days after cancer diagnosis. Cancer stage and grade are the strongest risk factors for AF. New onset AF after breast cancer increases all-cause and cardiovascular mortality. Take Home Message: AF incidence is higher in breast cancer patients and is associated with later stage and grade at diagnosis of breast cancer. Involving cardio-oncology in those who develop AF after cancer diagnosis should be encouraged to improve their cardiovascular and overall prognosis.

8 September 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
TWTracy E. Wiczer
Tracy E. Wiczer
LLLauren B. Levine
Lauren B. Levine
JBJessica Brumbaugh
Jessica Brumbaugh
JCJessica Coggins
Jessica Coggins
QZQiuhong Zhao
Qiuhong Zhao
Farrukh AwanFarrukh Awan
Farrukh Awan
Key Points: Ibrutinib increases the incidence of AF in patients with hematologic malignancies treated on or off a clinical trial. Patients with a history of AF and those with a high FHS-AF risk score are at highest risk for developing AF while on ibrutinib.